High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma
Open Access
- 17 March 2009
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 100 (7), 1144-1153
- https://doi.org/10.1038/sj.bjc.6604964
Abstract
The objective of this paper is to investigate the mesothelin expression level to the clinicopathological features, chemoresponse, and to the outcome of patients with epithelial ovarian carcinoma (EOC). Mesothelin mRNA was detected by real-time quantitative reverse-transcription PCR in 139 EOC patients. Clinical characteristics, histopathological items, responses to chemotherapy, progression-free survival (PFS), and overall survival (OS) were recorded. Tumours with advanced stages had higher mesothelin than those with early stages. The chemoresistant patients showed significantly higher mesothelin than did chemosensitive patients (2.81 vs 0.43, PP=0.006) and OS (3.72 (1.64–8.45), P=0.002) of the 139 EOC patients in multivariate analysis. In addition, patients in advanced stages with highly expressed mesothelin also had significantly worse OS, regardless of whether they had undergone optimal (13.85 (1.76–125.60), P=0.013) or suboptimal (4.47 (1.83–10.88), P=0.001) debulking surgery in multivariate analysis. Out results provide new evidence that mesothelin expression is associated with chemoresistance and with shorter disease-free survival and worse OS of patients with EOC.Keywords
This publication has 44 references indexed in Scilit:
- The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancerBritish Journal of Cancer, 2008
- Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinomaCancer, 2007
- Trophinin is a potent prognostic marker of ovarian cancer involved in platinum sensitivityBiochemical and Biophysical Research Communications, 2007
- Generation and characterization of an ascitogenic mesothelin-expressing tumor modelCancer, 2007
- Control of human mesothelin-expressing tumors by DNA vaccinesGene Therapy, 2007
- Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancerGynecologic Oncology, 2006
- Ovarian cancer: strategies for overcoming resistance to chemotherapyNature Reviews Cancer, 2003
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Time trends in ovarian cancer mortality in Europe (1955–1993): effect of age, birth cohort and period of deathEuropean Journal of Cancer, 2000
- Vascular endothelial growth factor in cervical carcinomaObstetrics & Gynecology, 1999